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INTRODUCTION
The peroxisome proliferator activated receptor (PPAR)g is
a ligand specific transcription factor. It plays an important
role in the regulation of diabetes mellitus (DM). It modulates
insulin sensitivity, cell growth, inflammation, and adipocyte
differentiation and lipid metabolism (1). PPARg agonist is
used worldwide for treatment of DM. In addition, PPARg
agonist has antifibrotic effects in both diabetic nephropathy
and non-diabetic nephropathy. Animal models of diabetic
nephropathy treated with PPARg agonist have demonstrat-
ed decreased proteinuria and glomerular matrix deposition
and glomerulosclerosis; these results appear to be indepen-
dent of the antidiabetic effect of PPARg (2, 3). In the 5/6-
nephrectomy model, activation of PPARg has been shown
to reduce glomerulosclerosis (4). In addition, in vitro exper-
iments have demonstrated that PPAR-g activation had anti-
proliferative (5) and antifibrotic effects on the mesangial cells
(6). Furthermore PPAR-g activation reduced type I collagen
synthesis and secretion. Its action probably was linked to a
TGF-b1-dependent mechanisms (7). Based on these results,
we speculate that the antifibrotic effects of PPAR-gare linked
to TGF-b. However, the mechanism involved in the antifi-
brotic effects has been little known. 
Tubulointerstitial lesion containing tubular atrophies and
interstitial fibrosis in the kidney are the final common pathways
that lead to progressive renal failure regardless of the prima-
ry cause of renal disease (8). The unilateral ureteral obstruc-
tion (UUO) model induces interstitial inflammation and fibro-
sis; it has been used as a model for tubulointerstitial fibrosis.
The expressions of tissue growth factor (TGF)-b and plas-
minogen activator inhibitor-1 (PAI-1) are increased in the
UUO model (9, 10) and with decreased fibrosis, their expres-
sion decreases.
In this study, we evaluated whether the PPARg agonist,
pioglitazone, had antifibrotic and antiinflammatory effects
in the UUO mouse model. In addition, we studied whether
there are synergistic effects with angiotensin receptor blocker
(ARB), widely used for anti-inflammatory and antifibrotic
treatment in kidney diseases. In addition, we evaluated the
mechanism involved in the antifibrotic effects of the PPARg
agonist that correlate with TGF-b and PAI-1.
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PPARg Agonist and Angiotensin II Receptor Antagonist Ameliorate
Renal Tubulointerstitial Fibrosis 
The peroxisome proliferator activated receptor (PPAR)g agonist is used as antidia-
betic agent with antihyperglycemic and antihyperinsulinemic actions. Beyond these
actions, antifibrotic effects have been reported. We examined antifibrotic effects of
PPARg agonist and interaction with angiotensin receptor antagonist in the unilater-
al ureteral obstruction (UUO) model. After UUO, mice were divided to four groups:
no treatment (CONT), pioglitazone treatment, L158809 treatment, and L158809+
pioglitazone treatment. On day 14, CONT mice showed severe fibrosis and all treated
mice showed decreased fibrosis. The immunohistochmistry of PAI-1, F4/80 and p-
Smad2 demonstrated that their expressions were increased in CONT group and
decreased in the all treated groups compared to CONT. PAI-1 and p-Smad2 deter-
mined from Western blotting, among treated groups, was decreased compared to
CONT group. The expression of TGF-b1 from real time RT PCR showed markedly
increased in the CONT group and decreased in all treated groups compared to CONT.
These data suggest the pioglitazone inhibited tubulointerstitial fibrosis, however, the
synergism between pioglitazone and L158809 is not clear. Considering decreased
expression of PAI-1 and TGF-b/Smad2 in the treated groups, PAI-1 and TGF-b are
likely linked to the decreased renal tubulointerstitial fibrosis. According to these results,
the PPARg agonist might be used in the treatment of renal fibrotic disease.
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ing Growth Factor Beta
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Animals
Adult male wild type C57BL/6 mice, 10 to 12 weeks of
age were used for the experiments. The mice were housed in
microisolator cages in a pathogen-free barrier facility. The
mice had free access to tap water and standard mouse chow
(RP5015; PMI feeds Inc, St. Louis, MO, USA) or prepared
chow containing the PPARg agonist, pioglitazone. The mice
were maintained in a temperature-controlled facility with 12-
hr light/12-hr dark cycles. All procedures were followed the
rules of the Inha University animal experiment committee. 
Experimental protocol
The mice underwent UUO (n=40) under general anesthe-
sia and sterile conditions (11). After the UUO, they were
divided into 4 groups. The first group (n=10) did not receive
any treatment (CONT). The second group (n=10) received
the PPAR-g agonist, pioglitazone, p.o. (30 mg/kg/day) (pio-
glitazone treated group). The third group (n=10) received
the angiotensin receptor antagonist, L158809 (1.5 mg/kg/
day, drinking water [DW]) (L158809 treated group). The
fourth group (n=10) received combined therapy including
pioglitazone and L158809 of the same dose (combined treat-
ment group). On day five or 14 days after the surgery, the mice
were sacrificed and both the obstructed and nonobstructed
contralateral kidneys were collected for morphological, im-
munostaining, and molecular assessment. Four mice were
underwent sham operation as normal controls. 
Histological examination
For light microscopy, the tissue fixed in 4% paraformalde-
hyde was embedded in paraffin and 4 μ m sections were pre-
pared. After Masson’s trichrome staining, the degree of tubu-
lointerstitial fibrosis and injury were scored from 0 to 4+ on
the day 5 specimens. Fibrosis and injury were assessed as 0
for 0%, 1 for <25%, 2 for 25 to 50%, 3 for >50 to 75%, and
4 for >75% for each field with tubulointerstitial fibrosis. Inter-
stitial fibrosis, in the cortex, was assessed by point counting
(12) in the cortical area on the day 14 specimens. All sections
were examined without knowledge of the treatment protocol.
Immunohistochemistry
For immunostaining for PAI-1, antigen retrieval was per-
formed using microwaves for 10 min. The slides were expos-
ed to Power Block (BioGenex Laboratories, San Ramon, CA,
USA) for 45 min and incubated with rabbit anti-rat PAI-1
antibody (1:50, American Diagnostica, Inc., Greenwich, CT,
USA) at 4℃ overnight followed by biotinylated goat anti-
rabbit immunoglobulin (BioGenex Laboratories) for 45 min
and peroxidase-conjugated streptavidin for 45 min. Diami-
nobenzidine was added as a chromogen. Positive PAI-1 stain-
ing was graded from 0 to 4+(grade 0, No significant increase,
diffuse very weak stain similar to nonobstructed kidney; grade
1, very weak focal staining, <5% increase staining; grade 2,
mild/moderate intensity in <20% of areas; grade 3, moderate
intensity in 20-50%; grade 4, moderate intensity >50%). 
Infiltration of macrophages was detected by rat anti-mouse
F4/80 antibody (1:2,000; Serotec Inc., Raleigh, NC, USA)
incubated at room temperature for 1 hr, followed by Envision
kit (Dako, Carpinteria, CA, USA). Infiltrating macrophages,
in the interstitium, were counted and expressed as the num-
ber of macrophages per high-power field. 
For immunostaining of phosphorylated Smad2 (p-Smad2),
antigen retrieval was performed by microwave for 10 min.
Rabbit anti-human p-Smad 2 (Cell Signaling Technology,
Beverly, MA, USA) was used at room temperature overnight
followed by Envision kit (Dako). Positive p-Smad2 staining
was graded from 0 to 3+ (grade 0, No significant increase,
diffuse very weak nuclear stain similar to nonobstructed kid-
ney; grade 1, nuclear staining with mild intensity <20%
increase staining; grade 2, nuclear staining with moderate
intensity in ≤50% of areas; grade 3, nuclear staining with
moderate intensity in >50%).
Western blot analysis 
1) p-Smad 2, b-actin and PAI-1: The proteins were extracted
using PRO-PREP protein extraction solution (Intron, Seong-
nam, Korea) from the frozen kidney tissues. The protein con-
centration was measured using Dc Protein Assay kit (Bio-
Rad Laboratories, Hercules, CA, USA). Remaining proce-
dures was performed to an established procedure (13). The
primary antibodies used were as follows: rabbit anti-p-Smad2
polyclonal antibody, 1:500 (Upstate Biotechnology, Lake
Placid, NY, USA), mouse anti-b-actin monoclonal antibody,
1:5,000, (Sigma, St. Louis, MO, USA), rabbit anti-PAI-1
antibody, 1:100 (American Diagnostica). 2) The intensities
of individual bands were semiquantified using the TINA
2.0 program.
Real time RT-PCR for TGF-b1
Total RNA was obtained from frozen mouse kidney tissues
(normal and obstructed kidney) using the TRIZOL (Invit-
rogen, San Diego, CA, USA) according to the manufacturer’s
protocols. Mouse b-actin mRNA was used as an internal con-
trol and also used to assess RNA integrity. 
One micrograms of total RNA was reverse transcribed into
cDNA using RT system kit (Promega, Madison, WI, USA).
Reverse transcription was carried out in a total volume of 25
mL containing 10 mM Tris-HCl, (pH 8.8), 50 mM KCl, 5
mM MgCl2, 1 mM each dNTPs, 0.5 mg oligo (dT) primers,
25 U RNase inhibitor, and 15 U AMV reverse transcriptase
36 J.-Y. Han, Y.-J. Kim, L. Kim, et al.for 1 hr at 37℃, followed by 10 min at 95℃. The polymerase
chain reaction (PCR) was performed using 1 mL cDNA in a
total volume of 25 mL in the presence of 12.5 mL 2×iQ Super-
mix (Bio-rad), 200 nM TGF-b primer set, 100 nM TGF-b
probe. The PCR condition was 40 cycles at 95℃ for 30 sec,
60℃ for 1 min using iCycler iQ real-time PCR detection
system (Bio-Rad). Amplification of b-actin was carried out
in parallel with the genes of interest. Each assay included a
no template control and all measurements were performed in
duplicate. All samples with a coefficient of variation >10%
were retested. Primers and probes used for Real-Time RT-
PCR were purchased from TIB MOLBIOL (Berlin, Germany)
and their sequences were represented as following.
1) TGF-b1; forward; 5′ -TTCAGGACTATCACCTACC-
TTTCC-3′
Reverse; 5′ -CGGGAACCCTCGGCAAAG-3′
Probe; 5′ -6FAM-AGACCCCACCCCACAAGCCTGC-
BHQ1-3′
2) b-actin; forward; 5′ -CTTCTTTGCAGCTCCTTCG-
TTG-3′
Reverse; 5′ -CGACCAGCGCAGCGATATC-3′
Probe; 5′ -HEX-TCCACACCCGCCACCAGTTCGC-
BHQ2-3′
The value of TGF-b measured relative to Ct value.
Statistics
Results are expressed as mean±SEM. Statistical differ-
ence was assessed by analysis of variance followed by Mann-
Whitney U-test. A P value <0.05 was considered to be sig-
nificant.
RESULTS
Tubulointerstitial fibrosis
The trichrome staining revealed interstitial fibrosis and
tubular atrophy at 5 days in all of the groups. There was no
significant statistical difference among the groups. On the
day 14, the interstitial fibrosis was markedly increased in the
CONT group (0.27±0.03). The pioglitazone treated group
revealed decreased fibrosis compared to CONT (0.15±0.02,
P<0.05 vs. CONT). The interstitial fibrosis was more dec-
reased in the L158809 treated group and combined treatment
group compared to CONT and pioglitazone treated group
(L158809 treated group; 0.06±0.004, combined treatment
group; 0.09±0.01, P<0.05 vs. CONT and pioglitazone treat-
ed group) (Fig. 1). 
The number of interstitial macrophages 
The number of macrophages was increased 5 days after
UUO compared to contralateral non- obstructed kidney. How-
ever, there was no significant difference among treated and
non-treatment groups. By 14-day, the number of macrophages
was significantly increased in the CONT group (117.9±9.5/
HPF). The all treated groups showed significantly small mac-
rophage numbers compared to CONT (pioglitazone treated
group 63.9±5.4/HPF, L158809 treated group 80.9±10.2/
HPF, combined treatment group 76.5±4.4/HPF, P<0.05
vs. CONT) (Fig. 2).
PAI-1 expression
PAI-1 expression of IHC was slightly increased at 5-day.
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Fig. 1. Tubulointerstititial changes in obstructed kidneys. (A) At day 5, tubulointerstitial fibrosis is slightly increased at all groups with no
significant difference among groups. At day 14, CONT mice show severe progressive fibrosis and three treated groups show decreased
fibrosis compared to CONT. a, sham operated kidney; b, CONT at day 5; c, pioglitazone treated group at day 5; d, L158809 treated group
at day 5; e, combined treatment group at day 5; f, CONT at day 14; g, pioglitazone treated group at day 14; h, L158809 treated group at
day 14; i, combined treatment group at day 14 (Masson-trichrome stain, ×200). (B) Point counting scoring of fibrosis at day 14 shows less
fibrosis in all treated groups compared to CONT (Comb; combined treatment group) (*P<0.05 vs. CONT). 
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*However, there was no statistical difference between the treat-
ed groups. The PAI-1 was detected at the cytoplasm of dam-
aged or atrophic tubular epithelial cells, interstitial inflam-
matory cells and parietal epithelial cells. Their expression was
significantly increased at 14-day in the CONT group (2.85
±0.12). PAI-1 expression cells were similar to the CONT
but PAI-1 intensity was decreased compared to CONT in the
pioglitazone treated groups (1.91±0.08, P<0.05 vs. CONT).
For the L158809 and in the combined treatment groups, the
PAI-1 expression patterns were similar to CONT. Its inten-
sity was decreased but there was no statistically significant
difference (L158809; 2.65±0.10, P=0.3 vs. CONT, com-
bined treated group; 2.52±0.16, P=0.06 vs. CONT) (Fig. 3).
The PAI-1 determined from Western blotting, among the
day 14 all treated groups (pioglitazone treated group, L158809
treated group, and combined treatment group), was decreased
compared to CONT group (P<0.05); the L158809 treated
group showed most decreased expression, the combined treat-
ment group had the second most decreased expression and
pioglitazone treated group had the smallest decrease in expres-
sion compared to CONT (Fig. 4). 
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Fig. 2. Interstitial macrophage numbers in obstructed kidneys at
day 14. CONT mice show markedly increased number of intersti-
tial macrophages and all treated groups show decreased num-
ber of macrophages compared to CONT (*P<0.05 vs. CONT).
Fig. 3. PAI-1 protein expression by Immunohistochemical staining. (A) PAI-1 expression is identified in the cytoplasm of atrophic tubular
epithelial cells, interstitial inflammatory cells and parietal epithelial cells of glomerulus. At day 5, PAI-1 expression is minimally increased with
no significant difference among groups. At day 14, PAI-1 expression is increased at CONT. At pioglitazone treated  group, the PAI-1 expres-
sions is decreased comparing to CONT. a, sham operated kidney; b, CONT at day 5; c, pioglitazone treated group at day 5; d, L158809
treated group at day 5; e, combined treatment group at day 5; f, CONT at day 14; g, pioglitazone treated group at day 14; h, L158809 treat-
ed group at day 14; i, combined treatment group at day 14 (immunohistochemical staining for PAI-1, ×200). (B) Semiquantative grading
of PAI-1 expression at day 14 shows significantly decreased PAI-1 expression only at the pioglitazone treated groups compared to CONT
(*P<0.05 vs. CONT). 
A B
abc
def
ghi
P
A
I
-
1
 
e
x
p
r
e
s
s
i
o
n
 
(
g
r
a
d
e
 
0
-
4
)
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
Sham CONT Pioglitazone L158809 Comb
*
Fig. 4. PAI-1 protein expression by western blotting at day 14. PAI-
1 expression is decreased at all treated groups compared to CONT
(*P<0.05 vs. CONT).
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PAI-1
b-actinp-Smad 2 expression
P-Smad2 expression of IHC, a marker of TGF-b signaling
activation, was detected at the nuclei of damaged or atrophied
tubular epithelial cells and interstitial inflammatory cells. Its
expression was not increased at day 5 compared to normal con-
trol. At day 14, their intensity was increased in the CONT
group. In the all of treated groups (pioglitazone treated group,
L158809 treated group, combined treatment group), the p-
Smad2 expressions were decreased compared to CONT (Fig. 5). 
For the day 14 specimens, the p-Smad2 from Western blot-
ting analysis showed that the markedly increased in the CO-
NT group compared to normal control and decreased in the
combined treatment group compare to CONT (Fig. 6).
TGF-b1 expression 
On the day 5, TGF-b1 expression was increased in all groups.
However, there was no statistically significant difference among
the groups. For the day 14 samples, the TGF-b1 expression
was increased more in the CONT group and decreased in all
of the treated groups (pioglitazone treated group, L158809
treated group, combined treatment group, P<0.05 vs. CONT).
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Fig. 5. P-Smad2 expression by Immunohistochemical staining. P-Smad2 is detected at the nuclei of tubular epithelial cells and interstitial
inflammatory cells. (A) At day 5, p-Smad2 expression of IHC at treated groups is not increased compared to normal control. Weak cyto-
plasm stainings are present at all groups. At day 14, p-Smad2 expression is increased at CONT. At all treated groups, the p-Smad2 expres-
sions are decreased compared to CONT. a, sham operated kidney; b, CONT at day 5; c, pioglitazone treated group at day 5; d, L158809
treated group at day 5; e, combined treatment group at day 5; f, CONT at day 14; g, pioglitazone treated group at day 14; h, L158809 treated
group at day 14; i, combined treatment group at day 14 (immunohistochemical staining for p-Smad 2, ×200). (B) Semiquantative grad-
ing of p-Smad2 expression at day 14 shows significantly decreased p-Smad2 expression at the all treated groups compared to CONT
(*P<0.05 vs. CONT) .
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Fig. 7. Real time RT PCR for TGF-b1 at day 14. TGF-b1 expression
shows markedly increased at the CONT and significantly decreases
at the all treated groups compared to CONT (*P<0.05 vs. CONT).
Fig. 6. P-smad 2 expression by western blotting at day 14. P-Smad2
expression blotting at combined treatment group is decreased
compared to CONT (*P<0.05 vs. CONT).
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p-Smad2
b-actinThe relative value for the real time RT PCR of TGF-b1 was
the following: CONT, 1.52±0.53; pioglitazone treated group,
0.83±0.12; L158809 treated group, 0.63±0.13; and com-
bined treated group, 0.54±0.06 (Fig. 7).
DISCUSSION
PPARg agonists are used worldwide for their antidiabetic
activity including the regulation of insulin sensitivity and
lipid metabolism. In addition to these effects, PPARg has
antifibrotic and anti-inflammatory effects. Clinical and ani-
mal studies have shown that PPARg agonists not only regu-
late insulin sensitivity but also may have a protective effect
against kidney damage, such as reduced microalbuminuria
and delaying progression to diabetic nephropathy in humans
with type 2 diabetes and diabetic animal model (2, 14-16).
These renoprotective effects appear to be independent from
blood glucose control activity of PPARg. In vitro studies
also have revealed that PPAR-g agonists can inhibit cell pro-
liferation and suppress the expression of extracellular matrix
components (7, 17). UUO is a well established experimen-
tal model of progressive tubulointerstitial fibrosis. In this
study, we observed the antifibrotic and anti-inflammatory
effects of PPARg agonist, pioglitazone. Pioglitazone had an
antifibrotic effect on the UUO kidney. The interstitial fibro-
sis was decreased in the pioglitazone-treated group compared
the CONT group.
The mechanism underlying the antifibrotic effects of the
PPARgagonist has little known. TGF-b has been known to be
increased in progressive renal disease and PAI-1 plays an im-
portant role in the progression of renal fibrosis. Angiotensin,
aldosterone, and TGF-b induce PAI-1 expression, and inhibi-
tion of these compounds resulted in decreased PAI-1 and scle-
rosis in experimental models of chronic kidney disease (18-
20). In this connection, we tried to evaluate that TGF-b and
PAI-1 were linked to the antifibrotic effects of pioglitazone.
The results of our study showed that PAI-1 and TGF-b
expression were increased in the UUO kidneys, and decreased
in all of the treatment groups including the PPARg agonist
treated group. Based on these results, the mechanism under-
lying the antifibrotic effects of pioglitazone appeared to be
correlated with the decrease of TGF-b and PAI-1. There are
several prior studies that support these findings. In vitro,
pioglitazone inhibited fibronectin production induced by
TGF-b in mesangial cells (7). PPARg agonists had an antifi-
brotic effect on human proximal tubular cells in a high glu-
cose environment by inhibiting the increase in AP-1 and
TGF-b1, and decreasing the production of the fibronectin
(21). The PPARg agonist also inhibited TGF-b1 mediated
alpha smooth muscle actin, fibronectin, and PAI-1 expression
in the mesangial cells (22). In the 5/6 nephrectomy model,
PPARg ameliorated the development of sclerosis and this
effect was linked to decreased TGF-b and PAI-1 (4). 
Our findings showed that the p-Smad2 expression was also
decreased in the PPARg agonist treated group. The Smad
proteins are essential mediators and regulators of the intra-
cellular signaling pathways, acting as transcription factors of
TGF-b-mediated responses, including the fibrotic process (23).
After TGF-b binds to the TGF-b receptor II, phosphoryla-
tion of the TGF-b receptor I, and the intracellular substrates,
Smad2 and Smad3, occurs. When activated, these Smads with
their common partner, Smad4 complexes, are translocated
to the nucleus, where they regulate transcriptional responses
together with additional DNA binding cofactors. An in vitro
study showed that PPARg agonists inhibited the Smad sig-
naling pathway in the renal fibroblasts and blocked TGF-
beta/Smad-mediated gene transcription in mesangial cells
(22). Therefore, PPARg appears to have antifibrotic effects
correlated with PAI-1, and TGF-b/Smad2 signaling. 
The PPARg agonist also has anti-inflammatory effects. Our
results showed that the number of infiltrated interstitial mac-
rophage was markedly decreased in the pioglitazone treated
groups. PAI-1 affects recruitment of interstitial macrophages
and myofibroblasts, a potential source of both PAI-1, TGF-b
and other profibrotic cytokines such as PDGFs, macrophage
chemoattractant protein-1 (MCP-1), osteopontin, and inte-
grins (24). Persistent infiltration of activated macrophages
is profibrotic and closely correlated with progressive fibrosis
in the kidney (25). Therefore inhibition of macrophage accu-
mulation can produce not only antiinflammatory but also
antifibrotic effects. 
Angiotensin II is involved in the pathogenesis of renal dis-
ease, through the regulation of two key processes inflamma-
tion and fibrosis. Treatment of angiotensin II receptor antag-
onist ameliorates the renal interstitial fibrosis caused by UUO
by decreasing the TGF-b and the number of interstitial mac-
rophages (26). We also evaluated the antifibrotic effects of
ARB, L158809. Renal interstitial fibrosis and the number
of infiltrating macrophage were decreased in the L158809
treated group. Interstitial fibrosis was decreased more in the
L158809 treated group compared to the pioglitazone treat-
ed group. However, the number of interstitial macrophages
was greater in the L158809 treated group than in the piogli-
tazone treated group. The PAI-1 and TGF-b expression were
also decreased in the L158809 treated group. However, the
synergistic effects of pioglitazone and L158809 were not clear;
a synergistic effect was only observed with TGF-b expression.
Combination of pioglitazone and L158809 is almost equal-
ly effective compared to their single applications concerning
attenuation of fibrosis, infiltration of macrophages, PAI-1 and
TGF-b/p-Smad2 expression after UUO. The synergistic effect
between pioglitazone and L158809 was not clear in our study.
The studies about synergism of these two drugs are few and
the results are still controversial. In vitro, combination ther-
apy of a PPARgagonist and an ARB suppresses proinflamma-
tory signaling and stimulates expression of Smad7 in human
peritoneal mesothelial cells (27). However, in vivo examina-
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ergistic effect between candesartan and pioglitazone (28). The
synergistic effect with ARB is not clear. It needs further inves-
tigation.
In the conclusion, the PPARg agonist inhibited tubuloin-
terstitial fibrosis and infiltration of interstitial macrophages
in UUO model. The findings of decreased expression of PAI-
1, TGF-b, and p-Smad2 in the treated groups, suggest that
PAI-1 and TGF-b/Smad2 were linked to the decreased renal
tubulointerstitial fibrosis observed. Therefore, PPARg ago-
nists might be used for the treatment of renal fibrotic dis-
eases other than those associated with diabetes mellitus. 
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